二甲双胍铬(Ⅲ)配合物对糖尿病合并非酒精性脂肪肝大鼠的影响

Effect of chromium(Ⅲ)metformin complex on diabetic rats with nonalcoholic fatty liver disease

为了研究二甲双胍铬(Ⅲ)配合物的生物活性,构建糖尿病合并非酒精性脂肪肝大鼠模型,实验8周后检测各组大鼠空腹血糖、血脂、胰岛素、转氨酶水平,组织病理学观察大鼠肝脏形态变化,蛋白印迹法检测大鼠肝脏Caspase-3蛋白的表达情况。实验结果:与模型组相比,铬(Ⅲ)配合物干预可显著降低大鼠空腹血糖、血脂、胰岛素、转氨酶水平,差异有统计学意义(p<0.05);可减轻大鼠肝脏细胞水肿、脂肪变性等病理变化,并且干预组大鼠肝脏Caspase-3蛋白的表达显著低于模型组(p<0.05)。说明铬(Ⅲ)配合物对糖尿病合并非酒精性脂肪肝大鼠具有一定的治疗和肝脏保护作用。

To investigate the biological activity of chromium(Ⅲ)metformin(CrMet)complex,and establish a rat model of diabetes mellitus with nonalcoholic fatty liver disease,the fasting blood glucose,blood lipid,insulin and transaminase level were detected in each group after 8 weeks.The morphological changes of the liver in the rat were observed by histopathology.The expression of Caspase-3 protein in rat liver was detected by Western blotting.The experiment results showed that CrMet intervention could significantly lower fasting blood glucose,blood lipid,insulin and transaminase level in the rats,compared with the model group.The difference was significant(P<0.05).CrMet intervention could alleviate the pathological changes such as liver edema and steatosis in rats.The expression of Caspase-3 protein in the liver of the intervention group was significantly lower than that in the model group(p<0.05).CrMet had certain therapeutic and liver protective effects on diabetic rats with nonalcoholic fatty liver.